Published in Blood Weekly, January 29th, 2004
"Abnormalities of the p53 gene are known to confer detrimental effects in CLL and are associated with short survival. We have used HDMP to treat 25 patients with advanced refractory CLL of whom 45% had p53 abnormalities shown by one or more methods: flow cytometry, fluorescent in situ hybridization, and direct DNA sequencing," investigators in England report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.